GSK Stock Rises 4% After Q2 Beat and $2.5 Billion Savings Plan

TLDR

• GSK Q2 turnover hit £8.41 billion, beating the £8.24 billion analyst consensus
• Core EPS of 50.5 pence topped the 47.1 pence forecast
• Specialty Medicines rose 14%, Vaccines up 8%; General Medicines fell 9%
• GSK launched a £1.9 billion ($2.52 billion) three-year cost-savings program
• Full-year 2026 guidance reaffirmed, with turnover growth expected at the upper half of 3%–5%

GSK stock climbed 4.2% on Tuesday after the British drugmaker reported second-quarter results that beat analyst expectations across the board and announced a major cost-cutting plan.

GSK plc, GSK

Q2 turnover came in at £8.41 billion, ahead of the £8.24 billion consensus. Core operating profit was £2.80 billion versus the £2.68 billion forecast.

Core profit before tax hit £2.68 billion, topping the £2.52 billion estimate. Core EPS of 50.5 pence beat the 47.1 pence consensus.

GSK Q2 2026 Earnings

-Adj EPS 50.5P (est 46.8P)

-Rev. GBP 8.41B (est GBP 8.25B)

-Vaccines Sales GBP 2.28B (Est GBP 2.1B)

-SHINGRIX Rev. GBP 888M (est GBP 867.8M)

… Continue reading the full article at the original source below.